Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma

作者：Faghfuri Elnaz; Faramarzi Mohammad Ali; Nikfar Shekoufeh; Abdollahi Mohammad^*

来源：Expert Review of Anticancer Therapy, 2015, 15(9): 981-993.

DOI：10.1586/14737140.2015.1074862

• melanoma
• monoclonal antibody
• nivolumab
• PD-1 receptor
• pembrolizumab

Malignant melanoma is an important issue in oncology due to its high incidence, high mortality, and resistance to systemic therapy; however, targeted immunotherapy has noticeably improved the survival rates of melanoma patients. Promising targeted immunotherapies for malignant melanoma include the blockade of immune checkpoints with antibodies targeting cytotoxic T lymphocyte-associated antigen 4 and the programmed cell death protein 1 pathway. The US FDA-approved antibody ipilimumab targets cytotoxic T lymphocyte-associated antigen 4; however, it was limited by toxicity and a low response. Nivolumab and pembrolizumab (formerly lambrolizumab), the two FDA-approved anti-programmed death-1 monoclonal antibodies, show highly durable response rates and long- term safety, validating the importance of the programmed cell death protein 1 pathway blockade for treatment of malignant melanoma.

• 出版日期2015